News

Roche reveals promising results for trontinemab, an Alzheimer antibody, showing significant amyloid plaque reduction in patients during ongoing trials.

A groundbreaking at-home brain stimulation device gains FDA approval, offering hope for adults with major depressive disorder through innovative treatment.

Valproate's role in treating bipolar disorder is questioned as evidence suggests better alternatives exist for managing acute mania and maintenance.

Explore the psychological impact of Pantone's 2026 color choice, "Cloud Dancer," and its implications for emotional well-being and societal unity.

Postoperative delirium often goes unrecognized, especially in older patients. Early detection and intervention are crucial for better outcomes.

New research suggests semaglutide may protect against lithium-induced renal injury, offering hope for safer bipolar disorder treatments.

Explore how transcranial magnetic stimulation enhances athletic performance and mental health, offering innovative solutions for athletes facing psychological challenges.

"But when I finally learned to feel everything, I became a psychiatrist who touches nothing but a patient’s hand at the first meeting and the final good bye..."

Tris Pharma's TRN-257, a low-sodium oxybate, offers a once-nightly treatment option for narcolepsy and idiopathic hypersomnia, enhancing patient care.

Psychiatric Times celebrates 40 years of impactful insights, exploring key topics in psychiatry, including medication management and emerging treatments.

Explore the challenges of protecting privacy in AI chatbots and discover expert insights on navigating data security in a profit-driven landscape.

Teva Pharmaceuticals has submitted an NDA to the FDA for extended-release injectable olanzapine for the treatment of schizophrenia.

Dr. Carrie Soloway's legacy inspires courage in transgender individuals, highlighting the ongoing challenges and triumphs in mental health and identity.

Recent trials reveal oral semaglutide fails to improve cognition or function in early Alzheimer disease, raising questions about its efficacy.

Newron Pharmaceuticals launches a pivotal study on evenamide, targeting treatment-resistant schizophrenia to improve patient outcomes and address unmet needs.

Psychiatric Times celebrates 40 years of advancing mental health care, offering insights, news, and community for psychiatric professionals. Join us in 2026!

Explore innovative solutions to combat burnout in health care, including coaching, psychedelics, and addressing administrative harm for lasting change.

Merck presents promising Phase 1 trial results for MK-2214, a novel Alzheimer treatment, showcasing its potential to slow disease progression.

American psychiatry struggles with understanding psychopathology, emphasizing the need to return to its roots for accurate diagnosis and effective treatment.

What were the top psychiatric hits of 2025?

Psychiatry needs compassionate, culturally competent leaders to address mental health challenges and promote innovative solutions for a healthier future.

Incannex Healthcare's PSX-001 shows promise in treating generalized anxiety disorder, offering innovative, effective solutions beyond traditional therapies.

A critical shortage of IV lorazepam disrupts psychiatric care, particularly for patients with catatonia, highlighting broader pharmaceutical supply chain issues.

A recent survey reveals that 13% of US youth use generative AI for mental health advice, highlighting its perceived benefits and potential risks.

New neuroimaging data reveals XPro1595's potential to combat neuroinflammation in early Alzheimer’s disease, offering hope for slowing progression.

Explore the complexities of mental illness, its definitions, and the limitations of current psychiatric diagnosis in understanding true psychopathology.

Bristol Myers Squibb expands patient enrollment in the ADEPT-2 study, exploring Cobenfy's potential for treating Alzheimer disease-related psychosis.

Explore impactful ways to contribute on Giving Tuesday, supporting mental health organizations dedicated to making a difference in psychiatry.

Meta-analysis identifies 2 antidepressants that separate from placebo and other antidepressants in relieving negative symptoms of schizophrenia

Adolescent cannabis use surges in Oklahoma, raising public health concerns amid rising THC potency and permissive regulations.